These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31604085)

  • 1. Production Process Development of Pseudorabies Virus Vaccine by Using a Novel Scale-Down Model of a Fixed-Bed Bioreactor.
    Nie J; Sun Y; Peng F; Li X; Yang Y; Liu X; Li Y; Liu C; Bai Z
    J Pharm Sci; 2020 Feb; 109(2):959-965. PubMed ID: 31604085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pseudorabies virus production using a serum-free medium in fixed-bed bioreactors with low cell inoculum density.
    Nie J; Sun Y; Peng F; Han F; Yang Y; Liu X; Liu C; Li Y; Bai Z
    Biotechnol Lett; 2020 Dec; 42(12):2551-2560. PubMed ID: 32816175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid process development of serum-free pseudorabies virus production with the Quality by Design approach.
    Nie J; Sun Y; Han F; Yang Y; Liu X; Liu C; Li Y; Bai Z
    Cytotechnology; 2020 Apr; 72(2):283-293. PubMed ID: 32086694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a high-yield live-virus vaccine production platform using a novel fixed-bed bioreactor.
    Berrie DM; Waters RC; Montoya C; Chatel A; Vela EM
    Vaccine; 2020 Apr; 38(20):3639-3645. PubMed ID: 32247568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioreactor production of rVSV-based vectors in Vero cell suspension cultures.
    Kiesslich S; Kim GN; Shen CF; Kang CY; Kamen AA
    Biotechnol Bioeng; 2021 Jul; 118(7):2649-2659. PubMed ID: 33837958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development, optimization, and scale-up of suspension Vero cell culture process for high titer production of oncolytic herpes simplex virus-1.
    Shen CF; Burney E; Gilbert R; Elahi SM; Parato K; Loignon M
    Biotechnol J; 2024 Jan; 19(1):e2300244. PubMed ID: 37767876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of an attenuated Chinese pseudorabies variant by dual deletion of TK&gE genes.
    Wang J; Song Z; Ge A; Guo R; Qiao Y; Xu M; Wang Z; Liu Y; Zheng Y; Fan H; Hou J
    BMC Vet Res; 2018 Sep; 14(1):287. PubMed ID: 30241529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum-free production of rVSV-ZEBOV in Vero cells: Microcarrier bioreactor versus scale-X™ hydro fixed-bed.
    Kiesslich S; Vila-Chã Losa JP; Gélinas JF; Kamen AA
    J Biotechnol; 2020 Feb; 310():32-39. PubMed ID: 32006630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two pseudorabies virus vaccines, that differ in capacity to reduce virus excretion after a challenge infection, in their capacity of reducing transmission of pseudorabies virus.
    Bouma A; De Jong MC; Kimman TG
    Vet Microbiol; 1997 Feb; 54(2):113-22. PubMed ID: 9057255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bartha-k61 vaccine protects growing pigs against challenge with an emerging variant pseudorabies virus.
    Zhou J; Li S; Wang X; Zou M; Gao S
    Vaccine; 2017 Feb; 35(8):1161-1166. PubMed ID: 28131396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of Ambr15 system for simulation of entire SARS-CoV-2 vaccine production process involving macrocarriers.
    Jayson A; Goldvaser M; Dor E; Monash A; Levin L; Cherry L; Lupu E; Natan N; Girshengorn M; Epstein E; Rosen O
    Biotechnol Prog; 2022 Sep; 38(5):e3277. PubMed ID: 35633106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A high-temperature passaging attenuated Pseudorabies vaccine protects piglets completely against emerging PRV variant.
    Liang C; Tong W; Zheng H; Liu F; Wu J; Li G; Zhou EM; Tong G
    Res Vet Sci; 2017 Jun; 112():109-115. PubMed ID: 28214681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine resistant pseudorabies virus causes mink infection in China.
    Wang GS; Du Y; Wu JQ; Tian FL; Yu XJ; Wang JB
    BMC Vet Res; 2018 Jan; 14(1):20. PubMed ID: 29351775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single dose glycoprotein D-based subunit vaccine against pseudorabies virus infection.
    Zhang T; Liu Y; Chen Y; Wang A; Feng H; Wei Q; Zhou E; Zhang G
    Vaccine; 2020 Sep; 38(39):6153-6161. PubMed ID: 32741670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of packed bed bioreactor systems in the production of viral vaccines.
    Rajendran R; Lingala R; Vuppu SK; Bandi BO; Manickam E; Macherla SR; Dubois S; Havelange N; Maithal K
    AMB Express; 2014; 4():25. PubMed ID: 24949260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a quadruple glycoprotein-deleted pseudorabies virus mutant for use as a biologically safe live virus vaccine.
    Mettenleiter TC; Klupp BG; Weiland F; Visser N
    J Gen Virol; 1994 Jul; 75 ( Pt 7)():1723-33. PubMed ID: 8021601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of virus yield as a strategy to improve rabies vaccine production by Vero cells in a bioreactor.
    Trabelsi K; Rourou S; Loukil H; Majoul S; Kallel H
    J Biotechnol; 2006 Jan; 121(2):261-71. PubMed ID: 16153733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy evaluation of two live virus vaccines against an emerging pseudorabies virus variant.
    Wang M; Wang L; Zhao Q
    Pol J Vet Sci; 2019 Dec; 22(4):639-645. PubMed ID: 31867931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-pH Endocytic Entry of the Porcine Alphaherpesvirus Pseudorabies Virus.
    Miller JL; Weed DJ; Lee BH; Pritchard SM; Nicola AV
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30355685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An approach to a FMD vaccine based on genetic engineered attenuated pseudorabies virus: one experiment using VP1 gene alone generates an antibody responds on FMD and pseudorabies in swine.
    Qian P; Li XM; Jin ML; Peng GQ; Chen HC
    Vaccine; 2004 Jun; 22(17-18):2129-36. PubMed ID: 15149769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.